Popular Articles

A Selection Of Opinions And Editorials
Obama"s Health Cost Illusion Wall Street Journal
buy viagra
FluoroPharma To Present Phase I Study Results Of Novel Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) Tracer
FluoroPharma Inc., a company developing breakthrough PET molecular imaging agents, announced that it will present Phase I data relating to the safety, dosimetry, and pharmacokinetics in human subjects of BFPET, its novel 18-F labeled PET tracer for myocardial perfusion imaging, at the Society of Nuclear Medicine 2009 Annual Meeting in Toronto.
News of the day
$500,000 Gruber Neuroscience Prize Awarded To Hall, Rosbash And Young
The 2009 Neuroscience Prize of The Peter and Patricia Gruber Foundation is being awarded to Jeffrey Hall, professor of neurogenetics at the University of Maine; Michael Rosbash, professor and director of the National Center for Behavioral Genomics at Brandeis University; and Michael Young, professor and head of the Laboratory of Genetics at Rockefeller University. On October 18, at the annual meeting of the Society for Neuroscience in Chicago, Illinois, these three distinguished scientists will receive this prestigious international award for their groundbreaking discoveries of the molecular mechanisms that control circadian (daily) rhythms in the nervous system. Their research was the first to establish a simple relationship between single genes and a complex behavior.
Health Insurance

Federal Appeals Court Rejects Lawsuit Against Abbott Over HIV/AIDS Drug Price Hike

Federal Appeals Court Rejects Lawsuit Against Abbott Over HIV/AIDS Drug Price Hike A federal appeals court on Tuesday rejected a lawsuit against Abbott Laboratories accusing the company "of antitrust violations over a sudden 400-percent price hike of a popular AIDS drug," the AP/ El Paso Times reports (7/7). Advocacy groups and drug benefit providers sued Abbott in 2004 alleging the "drugmaker raised the price of the HIV-fighting Norvir to stifle competition and boost sales of its own alternative, Kaletra. The company paid $10 million to settle the lawsuit and agreed to let the 9th U.S. Circuit Court of Appeals still determine if the price hike was an illegal business practice," writes AP/Minneapolis Star Tribune. A lawyer for the advocacy groups says they are still deciding whether to file an appeal (7/7). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):